[go: up one dir, main page]

WO2009120022A3 - 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물 - Google Patents

면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2009120022A3
WO2009120022A3 PCT/KR2009/001536 KR2009001536W WO2009120022A3 WO 2009120022 A3 WO2009120022 A3 WO 2009120022A3 KR 2009001536 W KR2009001536 W KR 2009001536W WO 2009120022 A3 WO2009120022 A3 WO 2009120022A3
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
immunopeptide
prophylaxis
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001536
Other languages
English (en)
French (fr)
Other versions
WO2009120022A2 (ko
Inventor
이경률
임종백
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocore Co Ltd
Original Assignee
Biocore Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocore Co Ltd filed Critical Biocore Co Ltd
Publication of WO2009120022A2 publication Critical patent/WO2009120022A2/ko
Publication of WO2009120022A3 publication Critical patent/WO2009120022A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 면역성 펩타이드 및 그 펩타이드를 포함하는 HPV 관련 질환 예방 또는 치료용 조성물에 관한 것으로 더욱 상세하게는 HPV type 16의 E7 단백질 유래 E7 면역성 펩타이드 및 그 펩타이드를 포함하는 HPV 관련 질환 예방 또는 치료용 조성물에 관한 것이다.
PCT/KR2009/001536 2008-03-28 2009-03-26 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물 Ceased WO2009120022A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0029256 2008-03-28
KR1020080029256A KR20090103571A (ko) 2008-03-28 2008-03-28 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물

Publications (2)

Publication Number Publication Date
WO2009120022A2 WO2009120022A2 (ko) 2009-10-01
WO2009120022A3 true WO2009120022A3 (ko) 2009-12-23

Family

ID=41114459

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001536 Ceased WO2009120022A2 (ko) 2008-03-28 2009-03-26 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물

Country Status (2)

Country Link
KR (1) KR20090103571A (ko)
WO (1) WO2009120022A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090125629A (ko) * 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
WO2016006873A1 (ko) * 2014-07-09 2016-01-14 연세대학교 산학협력단 인유두종바이러스 펩타이드의 자궁경부암 진단 및 치료 용도
AU2017338827B2 (en) 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
RU2020135968A (ru) 2018-04-05 2022-05-06 Джуно Терапьютикс, Инк. T-клеточные рецепторы и модифицированные клетки, экспрессирующие

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170644A1 (en) * 2001-05-04 2004-09-02 Bernard Mailere Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7201908B2 (en) * 2001-03-23 2007-04-10 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Modified HPV E6 and E7 genes and proteins useful for vaccination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7201908B2 (en) * 2001-03-23 2007-04-10 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Modified HPV E6 and E7 genes and proteins useful for vaccination
US20040170644A1 (en) * 2001-05-04 2004-09-02 Bernard Mailere Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHENHONG ZHANG.: "An Improved Fully Connected Hidden Markov Model for Rational", VACCINE DESIGN., 2005, UNIVERSITY OF SASKATCHEWAN (THESIS) *
SATOKO MORISHIMA ET AL.: "Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: The combined effects of bortezomib and interferon- y on the presentation of a cryptic epitope.", INTERNATIONAL JOURNAL OF CANCER., vol. 120, no. 3, 2006, pages 594 - 604 *
YI-FANG CHEN ET AL.: "Cytotoxic-T-Lymphocyte Human Papillomavirus Type 16 E5 Peptide with CpG-Oligodeoxynucleotide Can Eliminate Tumor Growth in C57BL/6 Mice.", JOURNAL OF VIROLOGY., vol. 78, no. 3, 2004, pages 1333 - 1343 *

Also Published As

Publication number Publication date
KR20090103571A (ko) 2009-10-01
WO2009120022A2 (ko) 2009-10-01

Similar Documents

Publication Publication Date Title
WO2009059325A8 (en) Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2010062396A3 (en) Virus like particle compositions and methods of use
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2009155001A3 (en) Wnt protein signalling inhibitors
EA025278B9 (ru) Антивирусная композиция против заключенных или незаключенных в оболочку днк- или рнк-вирусов
WO2010151799A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2009089635A9 (en) Treating neurodegenerative diseases with progranulin (pgrn)
IN2012DN00624A (ko)
WO2010151797A3 (en) Compounds for modulating rna binding proteins and uses therefor
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
WO2006015035A8 (en) Useful compounds for hpv infection
WO2007125105A3 (en) Benzamide glucokinase activators
WO2010055082A3 (en) New crystal form of sunitinib malate
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
IL210953A0 (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases, and uses thereof
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2011098778A8 (en) Peptides for vaccines against birch allergy
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
WO2009120022A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
WO2008075205A3 (en) Improved process for the preparation of voriconazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09725252

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09725252

Country of ref document: EP

Kind code of ref document: A2